Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 124 Results

Title
Intervention Indication Therapeutic Area Year Actions
Ciltacabtagene autoleucel for relapsed and refractory multiple myeloma Ciltacabtagene Autoleucel (JNJ-68284528; LCAR-B38M CAR-T cell therapy; LCAR-B38M; JNJ 4528) Multiple myeloma (MM) Haematological Cancer and Lymphomas , Haematology 2021 View  |  Download
Crizotinib for paediatric ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour Crizotinib (Xalkori; PF-02341066; Xalkor) Anaplastic large cell lymphoma (ALCL) , Myofibroblastic tumour Haematological Cancer and Lymphomas 2021 View  |  Download
Daratumumab (Darzalex) with lenalidomide and dexamethasone for multiple myeloma – first line Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2017 View  |  Download
Daratumumab (subcutaneous injection) for multiple myeloma Daratumumab (Darzalex; JNJ-54767414) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2019 View  |  Download
Daratumumab for the treating high-risk smouldering multiple myeloma Daratumumab (Darzalex; JNJ-54767414) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Daratumumab in addition to bortezomib, lenalidomide and dexamethasone for multiple myeloma – first line Bortezomib (Velcade; bortezomib mannitol boronic ester) , Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2020 View  |  Download
Daratumumab in addition to Bortezomib, Thalidomide and Dexamethasone for newly diagnosed Multiple Myeloma Bortezomib (Velcade; bortezomib mannitol boronic ester) , Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Thalidomide (Taldo) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Daratumumab in addition to pomalidomide and dexamethasone for relapsed or refractory multiple myeloma Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2020 View  |  Download
Daratumumab in combination with Bortezomib, Melphalan and Prednisone for Multiple Myeloma – first line Bortezomib (Velcade; bortezomib mannitol boronic ester) , Daratumumab (Darzalex; JNJ-54767414) , Melphalan , Prednisone (Decadron; Lodotra) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Dasatinib (Sprycel) tablets for children with type II variation, philadelphia positive acute lymphoblastic leukaemia Dasatinib (Sprycel; BMS 354825; dasatinib monohydrate) Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications